An optimal hydration volume (HV) that prevents contrast-induced acute kidney injury (CI-AKI) in patients with renal insufficiency and heart failure (HF) at a high risk of worsening HF (WHF) has not been determined. We aimed to determine a safe HV that prevents CI-AKI and WHF following coronary angiography (CAG) or percutaneous coronary intervention (PCI) in patients with renal insufficiency and HF. We recruited 1,307 patients with renal insufficiency and HF and investigated the relationships between the peri-procedural HV/weight (HV/W) ratio, and the risks of CI-AKI and WHF following CAG or PCI. Higher HV/W quartiles were associated with higher CI-AKI rates (Q1: 6.2%, Q2: 9.1%, Q3: 12.5%, and Q4: 18.7%; P < 0.001) and a greater likelihood of WHF (Q1: 2.2%, Q2: 2.7%, Q3: 4.9%, and Q4: 11.7%; P < 0.001). The multivariate analyses indicated that excessively high HV/W ratios were associated with moderately increased risks of CI-AKI (Q4 versus Q1: adjusted odds ratio [OR] 2.16, 95% confidence interval [CI] 1.17-4.00) and WHF (Q4 versus Q1: adjusted OR 3.09, 95% CI 1.21-7.88). The multivariate Cox regression analysis indicated that a higher HV/W ratio was associated with significantly increased long-term mortality (Q2 versus Q1: adjusted hazard ratio [HR] 2.36; Q3 versus Q1: adjusted HR 2.85; Q4 versus Q1: adjusted HR 2.94; all P < 0.05). In conclusion, an excessively high HV/W might be associated with a moderately increased risk of CI-AKI, WHF, and long-term mortality in patients with renal insufficiency and HF.
of CI-AKI. [8] [9] [10] The 2014 guidelines from the European Society of Cardiology recommend that patients with preexisting renal disease, who are undergoing CAG or PCI, should be administered saline hydration at a rate of 1 mL/ kg per hour 12 hours before and 24 hours after the procedure. 9) The 2010 European Society of Cardiology guidelines recommend a reduced saline hydration speed of 0.5 mL/kg per hour for patients with chronic HF (according to left ventricular ejection fraction [LVEF] < 40% or New York Heart Association class > 2) and chronic kidney disease (CKD) to prevent worsening HF (WHF). 11) However, little clinical evidence is available that supports these hydration durations and volumes for the prevention of CI-AKI without increasing the risk of WHF. Therefore, in the present study, we aimed to investigate the associations between hydration strength and CI-AKI and WHF to determine an effective and safe hydration volume (HV) for patients with renal insufficiency and HF.
Methods
Consecutive patients who were admitted for CAG or PCI at our institution from April 2009 to December 2013 were included in this prospective observational study. We enrolled patients aged !18 years who were undergoing CAG or PCI and had renal insufficiency (n = 1,307), which was defined as an eGFR < 90 mL/minute per 1.73 m 2 that was calculated using the Modification of Diet in Renal Disease formula, 12) and HF, which was defined as New York Heart Association or Killip class > 1 or a history of pulmonary edema. The exclusion criteria included lactation, pregnancy, presence of a malignancy, a history of cardiovascular surgery or endovascular repair, intravascular administration of contrast medium within 7 days before or 3 days after the procedure, end-stage renal disease or renal replacement therapy, missing pre-or postoperative creatinine values, and not using isotonic saline for hydration. Patients who did not have previous HF (n = 1,650), or whose renal function was normal (n = 1,185), which was defined as an eGFR !90 mL/minute per 1.73 m 2 , were also excluded.
Cardiac catheterization was performed in accordance with standard clinical practice. The contrast type and dose used were at the discretion of the interventional cardiologist based on the operative requirements. All of the patients received a continuous intravenous infusion of isotonic saline at a speed of 0.5 mL/kg per hour for at least 2-12 hours before and 6-24 hours after the procedure. All serum creatinine concentrations were measured on admission and on days 1, 2, and 3 after the procedure. The baseline eGFRs were calculated using the Modification of Diet in Renal Disease equation, and the HV/weight (HV/ W) ratios in mL/kg were calculated.
The follow-up events were carefully monitored and recorded through office visits and telephone interviews at 1, 6, 12, 24, 36, and 48 months after the coronary angiography procedure. The mean follow-up time was 2.25 ± 0.94 years (median 2.15, interquartile range [IQR] 1.62-2.93 years). The institutional research ethics committee approved the study, and all patients gave their written informed consent.
The primary endpoints were CI-AKI and WHF. CI-AKI was defined as an increase in serum creatinine level of !0.5 mg/dL or !25% from the baseline value within 48-72 hours of exposure to the contrast medium. 13) WHF was defined as at least 1 sign or symptom, or radiologic evidence of new, persistent, or worsening acute HF that required additional new intravenous therapy, including diuretics, inotropes, or vasodilators, or mechanical support during hospitalization that was targeted specifically at HF symptoms. 14) Major adverse clinical events (MACEs) were defined as mortality, non-fatal acute myocardial infarction, target vessel revascularization, and stroke.
The patients were assigned to 4 groups based on their HV/W ratio values. The analysis of variance (ANOVA) was used to analyze the normally distributed continuous variables, and the results are expressed as the mean ± standard deviation. The Kruskal-Wallis test was used to analyze the non-normally distributed continuous variables, and the results are presented as the median and interquartile range (IQR). Pearson's chi-squared test and Fisher's exact test were used to analyze the categorical data, and the results are expressed as frequency and percentage. Univariate analysis and multivariate logistic regression models involving stepwise selection and backward elimination were used to identify the predictors of CI-AKI and WHF. The Kaplan-Meier method was used to plot the cumulative mortality, and the differences between the curves were assessed using the log-rank test. Multivariate Cox regression analysis was used to calculate the hazard ratios (HRs) and their 95% confidence intervals (CIs). The statistical analyses were performed using IBM SPSS software, version 22.0 (IBM Corporation, Armonk, NY, USA) and R software, version 3.1.2 (R Core Team, Vienna, Austria). 15) Two-sided P values < 0.05 were considered statistically significant.
Results
The final analysis included 1,307 patients with renal insufficiency and HF. The mean age of the patients was 66.7 ± 10.1 years and 24.6% of the patients were women. Mean serum creatinine level was 107.1 ± 36.5 umol/L and mean LVEF was 55.6 ± 13.4% at baseline. The patients were categorized according to the HV/W ratio quartiles, hence, the hydration strengths, and their baseline and procedural characteristics are presented in Table I and Table  II . The HV/W ratio quartiles were as follows: Q1: < 7.94 mL/kg, Q2: 7.94-10.99 mL/kg, Q3: 10.99-17.24 mL/kg, and Q4: > 17.24 mL/kg. The groups with higher HV/W ratios comprised significantly older patients, and higher proportions of patients with diabetes mellitus, hypertension, anemia, and worse renal function, and the patients were administered more diuretics, used higher volumes of contrast media, and were more likely to undergo emergency PCI and have multivessel disease.
The CI-AKI rates showed significant differences among the HV/W ratio quartiles, with rates of 6.2%, 9.1%, 12.5%, and 18.7% in Q1, Q2, Q3, and Q4, respectively, (P < 0.001) (Table III) . Individuals with higher HV/W ratios were more likely to significantly exhibit WHF, with rates of 2.2%, 2.7%, 4.9%, and 11.7% for Q1, HYDRATION PREVENTING CI-AKI AND WHF Q2, Q3, and Q4, respectively, (P < 0.001). The incidence of MACEs during follow-up was significantly higher in the patients with higher HV/W ratios, with rates of 4.6%, 10.0%, 16 .3%, and 20.5% for Q1, Q2, Q3, and Q4, respectively, (P < 0.001).
The multivariate logistic regression analysis revealed that, compared with the Q1 HV/W ratio, a higher HV/W ratio quartile was associated with an increased risk of CI-AKI, with Q4 showing a significant difference (Q2 versus Q1: OR 1.23, 95% CI 0.63-2.40; Q3 versus Q1: OR 1.55, 95% CI 0.83-2.92; Q4 versus Q1: OR 2.16, 95% CI 1.17-4.00), after adjusting for 11 confounding variables that included age, diabetes mellitus, hypertension, eGFR, LVEF, anemia, the use of diuretics, emergency PCI, coronary lesions, multivessel disease, and contrast medium volume > 200 mL (Table IV) . After adjusting for age, the eGFR, LVEF, use of diuretics, emergency PCI, and multivessel disease, the multivariate logistic regression analysis revealed that, compared with the Q1 HV/W ratio, the higher HV/W ratio quartiles were associated with an upward trend of WHF, with Q4 showing a significant difference (Q2 versus Q1: OR 1.20, 95% CI 0.41-3.53; Q3 versus Q1: OR 1.12, 95% CI 0.40-3.11; Q4 versus Q1: OR 3.09, 95% CI 1.21-7.88) ( Table  V) .
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The mean follow-up period was 2.25 ± 0.94 years (IQR 1.62-2.93 years), and data were available for all of the patients who survived to discharge. Figure 1 shows the Kaplan-Meier survival curves for the study population based on the HV/W ratio quartiles. Compared with the Q1 HYDRATION PREVENTING CI-AKI AND WHF HV/W ratio, the cumulative mortality rates were significantly higher for the patients in the higher HV/W ratio quartiles (log-rank P < 0.001). Patients with CI-AKI or WHF were at a higher risk of mortality ( Figure 2 ). The multivariate Cox regression analysis showed that a higher HV/W ratio quartile was associated with significantly increased risk of death after PCI (Q2 versus Q1: adjusted HR 2.36, 95% CI 1.04-5.31, P = 0.039; Q3 versus Q1: adjusted HR 2.85, 95% CI 1.30-6.24, P = 0.009; Q4 versus Q1: adjusted HR 2.94, 95% CI 1.34-6.43, P = 0.007) (Figure 3) .
Discussion
In the current study, which may be the first to explore the optimal HV for patients with renal insufficiency and HF, the multivariate logistic regression analyses determined that excessive hydration strength may be associated with moderately increased risks of CI-AKI and postprocedural WHF in patients with renal insufficiency and HF who had undergone CAG or PCI. In addition, longterm mortality following CAG or PCI increased significantly as the HV/W ratio increased in patients with renal insufficiency and HF.
A number of prophylactic pharmacological agents have been investigated, but the evidence regarding their benefits in relation to CI-AKI prevention is controversial. 7) There has also been considerable interest in saline hydration optimization therapies that protect against CI-AKI. The findings from the POSEIDON study in which patients undergoing cardiac catheterization were administered a bolus of fluid before the procedure followed by maintenance infusions over the next 4 hours, 16) showed that left ventricular end-diastolic pressure-guided volume expansion was effective and safe, that it significantly reduced the risk of CI-AKI compared with that in the control patients (6.7% versus 16.3%, P = 0.005), and that the total intravenous saline HV in the left ventricular end-diastolic pressure-guided group was significantly higher than that in the control group (1,727 ± 583 mL versus 812 ± 142 mL, P < 0.001). 16) The RenalGuard fluid infusion system is another alternative fluid management system that combines the effects of furosemide-forced diuresis and intravenous saline infusion and matches the latter with the urine outputs from patients with CKD. 17) The occurrence of CI-AKI was significantly higher in the control group compared with that in the furosemide with matched hydration group (18% versus 4.6%, P = 0.005), and the control group consumed a lower mean volume of saline (1,742 ± 290 mL) compared with that consumed by the furosemide with matched hydration group (3,995 ± 1,401 Figure 3 . Multivariate Cox regression analysis indicated that the higher hydration volume/weight quartiles were associated with an increased risk of death after coronary angiography or percutaneous coronary intervention. Q indicates quartile; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; HR, hazard ratio; and CI, confidence interval. mL). A lower incidence of cumulative in-hospital clinical complications was evident in the furosemide with matched hydration group compared with that in the control group (8% versus 18%, P = 0.052).
A recent study investigated the central venous pressure-guided hydration method for patients with chronic HF and CKD, 18) and the findings showed that the risk of CI-AKI was significantly lower in the central venous pressure-guided group than in the control group (15.9% versus 29.5%, P = 0.006), and that the central venous pressure-guided hydration method did not increase the incidence of acute HF compared with that in the control group (3.8% versus 3.0%, P = 0.500). The findings from all of these studies demonstrate that using higher HVs lowers the CI-AKI incidence. However, these studies involved invasive procedures that are difficult to apply to most patients who undergo CAG or PCI. In addition, these results do not concur with those from our previous study that showed after adjusting for the confounding variables, excessively high HVs did not decrease the risk of CI-AKI in patients with renal insufficiency. 19) The results may have been a consequence of the presence of many baseline variables that are associated with a CI-AKI risk in the highest hydration group, including a lower eGFR and a higher proportion of patients with a LVEF < 40%. 20) The guidelines published by the European Society of Urogenital Radiology recommend prophylactic intravenous hydration administered at 1.0-1.5 mL/kg per hour at least 6 hours before and after the administration of the contrast medium for patients who are at risk for acute kidney injury. 21) Although the guidelines published by the American College of Cardiology and the European Society of Cardiology recommend that the hydration speed should be halved to 0.5 mL/kg per hour to prevent WHF in patients with chronic HF, that is, a LVEF <40%, and CKD, little evidence is available that enables the most appropriate hydration therapy to be defined, which includes that generated from investigations into the relationship be-tween the hydration strength and adverse outcomes in patients with renal insufficiency and HF. The findings of the present study showed that patients with renal insufficiency and HF had a high incidence of CI-AKI, and that this incidence increased in individuals with higher HV/W ratios, which were associated with long-term mortality. Moreover, the findings demonstrated a higher rate of WHF as the HV/W ratio increased. After adjusting the models for the confounding variables, such as renal and cardiac dysfunction and diabetes mellitus, the multivariate analysis showed that although there were upward trends in the incidence of CI-AKI and WHF, Q4 was the only group of patients with renal insufficiency and HF that showed significant differences in relation to the CI-AKI and WHF incidence rates. In addition, the risk of death increased as the CI-AKI and WHF progressed.
The present findings indicate that determining the optimal rate and volume of intravenous fluid delivery presents a significant challenge, and that underhydration as well as overhydration can increase the risk of CI-AKI. Different mechanisms are involved in the complex pathophysiology that underlies CI-AKI, including the direct toxic effects of the contrast medium, vasoconstriction, oxidative stress, and medullary ischemia. 7, 22) The benefits of intravenous saline hydration include the enhanced washout of the contrast medium through the kidney, improvements in the tissues' resistance to reactive oxygen species, and reductions in the systemic and regional vasoconstrictor forces. 23, 24) A higher urine flow rate may reduce the amount of time the tissues are exposed to the contrast medium and it may mitigate the direct toxic effects of the contrast medium on the renal tubular cells. 25) Many studies have shown that higher levels of hydration reduce the incidence of CI-AKI in patients with renal insufficiency. Unfortunately, too much fluid that causes fluid overload can have deleterious effects on patients with impaired cardiac function. 25) The mechanisms by which fluid overload contributes to the progression of CI-AKI have been explored. Physiologically, fluid overload may result in renal interstitial edema and increasing renal interstitial pressure, which would reduce renal blood flow and destroy the architecture of the renal tissues, 26, 27) and these effects would continue to influence local oxygen exchange and lead to diffuse metabolic dysfunction.
The interactions between cardiac and renal dysfunction may be critical for disease progression and prognosis. [28] [29] [30] Renal insufficiency and HF frequently coexist, because of their common risk factors and common pathogenic mechanisms, including the activation of the sympathetic nervous system and the renin-angiotensin system, inflammation, and oxidative stress. [31] [32] [33] For patients with renal insufficiency and HF, it is important but difficult to implement a safe HV. The findings from research have confirmed that fluid overload plays an important role in the pathogenesis of WHF. 34, 35) Fluid overload would aggravate the burden on the heart by increasing the intraventricular pressure and myocardial stretch, and by activating the neuroendocrine system. High ventricular filling pressures may negatively affect cardiac function, which would increase the occurrence of WHF and cause subendocardial ischemia and impaired cardiac venous drainage from the coronary veins, leading to left ventricular remodeling and lower thresholds for arrhythmias. 34, 35) Therefore, to prevent CI-AKI and WHF, safe and effective HVs are necessary to facilitate further investigations of patients with renal insufficiency and HF.
This study has several limitations. First, it was a prospective, observational, single-center study, and the evidence generated may not be as robust as that from a randomized, controlled trial. In addition, our definition of WHF included evidence of an escalation of therapy, but we could not describe the reasons underlying the need for therapy escalation and we cannot be certain that all care escalations were for WHF. Furthermore, we were unable to calculate the true total HVs, which should include oral water intake data that were missing in this study, to evaluate the effect of total hydration. The present study findings showed that an excessively high HV might be associated with a moderately increased risk of CI-AKI, post-procedural WHF, and, even, long-term mortality in patients with renal insufficiency and HF. Moreover, CI-AKI and WHF were significantly associated with an increase in the risk of long-term mortality. The benefits of controlling HVs in patients with renal insufficiency and HF must be investigated in further large-scale, multicenter, randomized, controlled trials.
